Table 2

Efficacy of H. pylori eradication in the risk reduction of gastric cancer in randomised trials

StudyCountry/trial start yearMean age (years)/proportion of male subjects (%)Regimen/ duration (days)Eradication rate in treated/non-treatedWith precancerous lesion at baseline (%)*Follow-up period (years)GC/total in treated vs non-treatedRisk ratio (95% CI)
Primary prevention Meta-analysis 0.55 (0.42 to 0.74)
 Correa et al 28 Columbia/199451/46%BAM/14 days; PAC/14 days (second)74% (1st+2nd) /15%100%6 years3/437 vs 2/4151.42 (0.24 to 8.48)
 Leung 2004 and Zhou et al 30 31 China/199652/48%PAC/7 days74.5%/9.3%44.6%10 years2/276 vs 7/2760.29 (0.06 to 1.36)
 Wong et al 3 China/199442/54%PAM/14 days83.7%38.4%7.5 years7/817 vs 11/8130.63 (0.25 to 1.63)
 Saito et al 32 Japan/n.a.20-59Y/n.a.PAC/7 days74.4%NA≥4 years2/379 vs 3/3130.55 (0.09 to 3.27)
 Ma et al and Li et al 33 34 China/199547/50%PA/14 days74%/NA
Y7: 46%/10%
75.7%22 years41/1130 vs 78/11280.52 (0.36 to 0.76)
 Wong et al 35 China/200253/46%PAC/7 days71.3%/NA100%5 years6/510 vs 3/5142.02 (0.51 to 8.02)
 Choi et al 5 Korea/201249/50%PAC/7 days70.1%/7.1%57.4%9 years10/912 vs 23/9140.44 (0.21 to 0.91)
Secondary prevention Meta-analysis 0.48 (0.33 to 0.69)
 Fukase et al 38 Japan/200169/76%PAC/7 days74.9%/5%75%/49%3 years8/272 vs 24/2720.33 (0.15 to 0.73)
 Choi et al 39 Korea/200560/68%PAC/7 days82.6%/10.5%66.1%/75.7%6 years18/444 vs 36/4570.52 (0.30 to 0.89)
 Choi et al 4 Korea/200360/75%PAC/7 days80.4%/5.4%80.2%/54.7%6 years14/194 vs 27/2020.54 (0.29 to 1.00)
  • *the extent and severity of precancerous lesions varied among studies.

  • BAM, bismuth, amoxicillin and metronidazole; GC, gastric cancer; NA, not available; PAC, proton pump inhibitor, amoxicillin, clarithromycin; 1st+2nd, overall eradication rates.